Epigral Ltd Reports Strong Revenue Growth Amid Profit Decline

Epigral Ltd reported a net profit of Rs 82 crore for Q4 FY26, a decline from Rs 87 crore the previous year. Despite this, revenue rose by 17% to Rs 736 crore, a company record. Strong demand and cost stabilization helped boost EBITDA margins. Shares rose over 10% following this financial news.

Epigral Ltd has announced a net profit of Rs 82 crore for the January-March quarter of 2025-26, marking a decline of nearly 6% from Rs 87 crore recorded during the same period last year. Despite the dip in profit, the company achieved a remarkable 17% increase in revenue, reaching a record Rs 736 crore for the quarter.

This revenue surge is attributed to a 15% sequential rise and a 14% year-on-year volume growth, explained Chairman and Managing Director Maulik Patel. This impressive performance is reflective of robust demand conditions and a full recovery following scheduled maintenance in the previous quarter, with enhanced utilization levels and stabilized raw material costs supporting EBITDA margins at 23%.

The board has approved a final dividend of Rs 5 per share for FY26. Following the announcement, shares of the integrated chemical manufacturer climbed over 10%, closing at Rs 1,329.45 on the BSE.